Skip to main content

Advertisement

Table 3 Economic evaluation of antimicrobial central venous catheters: incremental costs and health outcomes under baseline analysis

From: Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision

Catheter type Infections avoideda ICU bed days releaseda Costs saveda (2006 AUD) QALYs gaineda ICER Average monetary net benefitsb (95% confidence interval)
Uncoated       390,664 (371,984 to 408,416)
CH/SSD (ext) 8.4 18.1 $93,281 0.91 Dominated 391,212 (372,736 to 408,687)
CH/SSD (int/ext) 7.4 15.9 $51,126 0.80 Dominated 391,030 (372,467 to 408,574)
SPC 11.4 24.6 $120,062 1.23 Dominated 391,206 (372,687 to 408,772)
MR 15.2 32.8 $130,289 1.64 Cost-saving 391,612 (373,159 to 408,861)
  1. aResults presented per 1,000 catheters; bMonetary net benefits reported per catheter assuming a willingness-to-pay for a QALY of AUD $40,000.
  2. CH/SSD, chlorhexidine silver sulfadiazine; ICER, incremental cost effectiveness ratio; ICU, intensive care unit; int/ext, internally and externally coated; QALY, quality-adjusted life year; MR, minocycline and rifampicin; SPC, silver, platinum and carbon.